MONTRÉAL, Dec. 19, 2025 /PRNewswire/ -- Vision Marine Technologies Inc. (the "Company", "Vision Marine", "we", "us", "our") (Nasdaq: VMAR), a leader in high-voltage electric marine propulsion systems with a multi-brand boat retail and service platform, today announced the closing of its previously announced best- efforts public offering of 32,000,000 units at a public offering price of $0.30 per unit (inclusive of the pre- funded warrant exercise price), for gross proceeds of $9,600,000 before deducting pla ...

LONDON, Ontario, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced the pricing of its underwritten U.S. public offering (the “Offering”) of 1,739,130 common shares, together with accompanying warrants to purchase 869,565 common sha ...

LONDON, Ontario, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (Nasdaq: ADUR) (CSE: ACT) (FSE: 9D5), a clean technology company using the power of chemistry to transform lower-value feedstocks, like waste plastics, heavy bitumen, and renewable oils, into resources for the 21st century, today announced the pricing of its underwritten U.S. public offering (the “Offering”) of 1,739,130 common shares, together with accompanying warrants to purchase 869,565 common sha ...

BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof) and accompanying common stock warrants to purchase an aggrega ...

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES FINAL PROSPECTUS WILL BE ACCESSIBLE ON SEDAR+ TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, is pleased to announce the pricing and terms of its previously announced public offering. The ...

公开募股定价详情 - Biodexa Pharmaceuticals PLC宣布进行一项最大努力承销的公开募股 募股单位包括157,000个ADS单位及2,891,781个预融资单位 [2] - 每个ADS单位发行价为3.28美元 每个预融资单位发行价为3.2799美元 募股单位中的证券可立即分离并单独发行 [2] - 本次发行预计将为公司带来总额约1000万美元的毛收益 净收益将用于资助研发项目、营运资金及其他一般公司用途 [3] 募股单位构成与条款 - 每个ADS单位包含1份美国存托凭证及2份L系列认股权证 每份ADR代表公司100,000股普通股 [2] - 每个预融资单位包含1份可购买1份ADS的预融资认股权证及2份L系列认股权证 [2] - 每份L系列认股权证在发行后可立即行权 行权价为每份ADS 3.28美元 有效期为发行日起五年 [3] 发行时间与安排 - 本次发行预计于2025年12月19日完成 需满足惯例交割条件 [4] - Maxim Group LLC担任此次发行的独家配售代理 [4] - 本次发行依据已向美国证券交易委员会提交并生效的F-1表格注册声明进行 [5] 公司业务与研发管线 - Biodexa是一家临床阶段生物制药公司 专注于开发针对未满足医疗需求的创新产品管线 [7] - 公司主要研发项目包括：用于治疗家族性腺瘤性息肉病和非肌层浸润性膀胱癌的eRapa 用于治疗1型糖尿病的tolimidone 以及用于治疗侵袭性罕见/孤儿脑癌适应症的MTX110 [7] - eRapa是雷帕霉素的口服胶囊制剂 是一种mTOR抑制剂 [8] - Tolimidone是一种口服、强效、选择性的Lyn激酶抑制剂 在糖尿病动物模型中通过胰岛素增敏作用展示出血糖控制潜力 [9] - MTX110是组蛋白去乙酰化酶抑制剂帕比司他的可溶制剂 该专有制剂可通过对流增强递送技术绕过血脑屏障 将化疗剂量药物直接递送至肿瘤部位 [10][11] - 公司拥有三项专有药物递送技术 致力于改善药物的生物递送和生物分布 总部及研发设施位于英国卡迪夫 [11]

公司融资公告 - Vision Marine Technologies Inc (NASDAQ: VMAR) 宣布了一项尽力承销的公开发行定价 发行32,000,000个单位 每个单位包括一股普通股（或一份预融资认股权证作为替代）和半份认股权证 每个单位公开发行价格为0.30美元 预计总收益为9,600,000美元（扣除承销商费用和发行费用前）[1] - 每份完整的认股权证赋予持有人以每股0.375美元的行权价购买一股普通股的权利 认股权证自发行日起五年后到期 此次发行预计于2025年12月19日结束[1] - 普通股（或预融资认股权证）与认股权证在发行中必须一并购买 但将分开发行 由于公司只发行完整的认股权证 投资者必须购买偶数个单位[1] 资金用途与发行安排 - 公司计划将此次发行所得款项主要用于一般公司用途和营运资金 具体包括库存管理 偿还其库存融资信贷额度 一般行政开支以及推进其E-Motion™电动动力总成技术的专利申请[2] - ThinkEquity担任此次发行的唯一配售代理[2] - 与此批证券相关的F-1表格注册声明（文件号333-291955）已向美国证券交易委员会提交 并于2025年12月17日生效 此次发行仅通过招股说明书进行[2] 公司业务概览 - Vision Marine Technologies Inc 是一家海洋技术和零售集团 在内燃机和电动船领域提供优质的划船体验[4] - 公司通过其E-Motion™高压推进平台和Nautical Ventures零售网络 提供了一个涵盖推进系统、零售、服务和水上消费者互动的集成生态系统[4]

公司融资活动 - Actelis Networks公司于2025年12月17日宣布其普通股公开发行的定价，发行总量为6,250,000股普通股（或等额的预融资认股权证），并附带可购买最多6,250,000股普通股的认股权证，合并公开发行价格为每股0.80美元 [1] - 认股权证的行权价格为每股0.80美元，发行后即可行权，有效期为五年，此次发行预计于2025年12月19日左右完成 [1] - 此次发行的总收益预计为500万美元，需扣除配售代理费及其他发行费用，公司计划将净收益用于一般公司用途 [2] - H.C. Wainwright & Co. 担任此次发行的独家配售代理 [2] 监管与法律文件 - 与此发行相关的S-1表格注册声明（文件号333-292119）已于2025年12月17日被美国证券交易委员会宣布生效 [3] - 发行仅通过构成有效注册声明一部分的招股说明书进行，初步招股说明书已提交给SEC，最终招股说明书的电子版可在SEC网站获取或联系配售代理获取 [3] 公司业务概况 - Actelis Networks是混合光纤、网络硬化解决方案的市场领导者，专注于为广域物联网应用提供快速部署，其应用领域包括政府、智能交通系统、军事、公用事业、铁路、电信和园区网络 [5] - 公司的创新产品组合通过混合光纤-铜缆网络，提供了光纤级的性能以及灵活性和成本效益 [5] - 通过其“网络感知网络”计划，公司为所有边缘设备提供基于人工智能的网络监控和保护，以增强网络安全性和弹性 [5]

ENGLEWOOD, CO / ACCESS Newswire / December 15, 2025 / Lightwave Logic, Inc. (Nasdaq:LWLG) (the "Company"), a technology platform company leveraging its proprietary electro-optic (EO) polymers to transmit data at higher speeds with less power in a small form factor, today announced that it is proposing to offer and sell its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the common stock offered in the publi ...

ORLANDO, Fla., Dec. 12, 2025 /PRNewswire/ -- LightPath Technologies, Inc. (NASDAQ: LPTH) ("LightPath," the "Company," "we," or "our"), a leading provider of next-generation optics and imaging systems for both defense and commercial applications, today announced the pricing of an underwritten public offering of 7,750,000 shares of its Class A common stock at a price to the public of $7.75 per share for gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and ot ...